AstraZeneca

News

AstraZeneca links with Absci on AI for biologics discovery

AstraZeneca has agreed a deal worth up to $247 million with US generative artificial intelligence (GenAI) company Absci that will focus on the discovery of a new antibody-

News

AZ drops two trials aimed at expanding Lokelma’s label

AstraZeneca has decided to abandon two phase 3 trials of its drug to reduce high levels of potassium in the blood (hyperkalaemia) – Lokelma – in patients with kidney disea

News

Lifeline for Wolman disease kids as NICE backs Alexion drug

Infants with a rare and fatal congenital disorder called Wolman disease in England and Wales will soon have access to a new drug via the NHS that can dramatically extend t

News

AstraZeneca joins KRAS push in cancer with Chinese deal

AstraZeneca has added to its oncology pipeline by licensing a small-molecule KRAS inhibitor from Chinese biotech Usynova for $24 million upfront.

News

AZ launches digital clinical trials business

AstraZeneca has launched a separate business unit that will take what the drugmaker has learned from running digitally-powered clinical trials and offer that experience to

News

AZ first to AKT finish line, but FDA clears narrow label

AstraZeneca has claimed FDA approval for its first-in-class pan-AKT inhibitor capivasertib, getting a green light for the drug as a treatment for breast cancer, but with a

AstraZeneca links with Absci on AI for biologics discovery

AZ drops two trials aimed at expanding Lokelma’s label

Lifeline for Wolman disease kids as NICE backs Alexion drug

AstraZeneca joins KRAS push in cancer with Chinese deal

AZ launches digital clinical trials business

AZ first to AKT finish line, but FDA clears narrow label

CDC panel votes to scrap hepatitis B birth dose advice

How to meet your physicians where they are online

AstraZeneca

Editor's Picks